ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

ClinicalTrials.gov ID: NCT02899052

Public ClinicalTrials.gov record NCT02899052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Study identification

NCT ID
NCT02899052
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • Carfilzomib Drug
  • Dexamethasone Drug
  • Venetoclax Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 18, 2017
Primary completion
May 31, 2027
Completion
May 31, 2027
Last update posted
Aug 4, 2025

2017 – 2027

United States locations

U.S. sites
18
U.S. states
16
U.S. cities
18
Facility City State ZIP Site status
University of Alabama at Birmingham - Main /ID# 151405 Birmingham Alabama 35233
University of Arkansas for Medical Sciences /ID# 151399 Little Rock Arkansas 72205
Memorial Healthcare System /ID# 224862 Hollywood Florida 33021-3513
Winship Cancer Institute of Emory University /ID# 161710 Atlanta Georgia 30322
The University of Chicago Medical Center /ID# 151395 Chicago Illinois 60637-1443
Indiana Blood & Marrow Transpl /ID# 218862 Indianapolis Indiana 46237
Duplicate_University of Kentucky Chandler Medical Center /ID# 151407 Lexington Kentucky 40536
Central Maine Medical Center /ID# 218856 Lewiston Maine 04240
Duplicate_University of Maryland School of Medicine /ID# 159721 Baltimore Maryland 21201-1544
Oncology Hematology Associates (OHA) - Springfield /ID# 218855 Springfield Missouri 65807-5287
Washington University-School of Medicine /ID# 222651 St Louis Missouri 63110
Duke Cancer Center /ID# 162062 Durham North Carolina 27710-3000
University of Pennsylvania /ID# 151768 Philadelphia Pennsylvania 19104-5502
University of Texas Southwestern Medical Center /ID# 218336 Dallas Texas 75390-7208
Baylor Scott & White Medical Center- Temple /ID# 218252 Temple Texas 76508-0001
University of Utah /ID# 151397 Salt Lake City Utah 84112-5500
Duplicate_VA Puget Sound Healthcare Syst /ID# 155369 Seattle Washington 98108
Aurora Health Care, Aurora Cancer Center /ID# 209612 Wauwatosa Wisconsin 53226-3436

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02899052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 4, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02899052 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →